113 related articles for article (PubMed ID: 27346522)
1. No Advantage in Survival With Targeted Therapies as Maintenance in Patients With Limited and Extensive-Stage Small Cell Lung Cancer: A Literature-Based Meta-Analysis of Randomized Trials.
Roviello G; Zanotti L; Cappelletti MR; Gobbi A; Senti C; Bottini A; Generali D
Clin Lung Cancer; 2016 Sep; 17(5):334-340. PubMed ID: 27346522
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Lee SM; Woll PJ; Rudd R; Ferry D; O'Brien M; Middleton G; Spiro S; James L; Ali K; Jitlal M; Hackshaw A
J Natl Cancer Inst; 2009 Aug; 101(15):1049-57. PubMed ID: 19608997
[TBL] [Abstract][Full Text] [Related]
4. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
6. Duration of chemotherapy for small cell lung cancer: a meta-analysis.
Zhou H; Zeng C; Wei Y; Zhou J; Yao W
PLoS One; 2013; 8(8):e73805. PubMed ID: 24023692
[TBL] [Abstract][Full Text] [Related]
7. New targeted therapies and small-cell lung cancer.
Rossi A; Maione P; Palazzolo G; Sacco PC; Ferrara ML; Falanga M; Gridelli C
Clin Lung Cancer; 2008 Sep; 9(5):271-9. PubMed ID: 18824449
[TBL] [Abstract][Full Text] [Related]
8. Second-line treatments of small-cell lung cancers.
Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
[TBL] [Abstract][Full Text] [Related]
9. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
Bozcuk H; Artac M; Ozdogan M; Savas B
Cancer; 2005 Dec; 104(12):2650-7. PubMed ID: 16284984
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
11. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE
J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241
[TBL] [Abstract][Full Text] [Related]
12. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.
Roviello G; Sigala S; Sandhu S; Bonetta A; Cappelletti MR; Zanotti L; Bottini A; Sternberg CN; Fox SB; Generali D
Eur J Cancer; 2016 Jul; 61():111-21. PubMed ID: 27162152
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer.
Lin H; Li L; Luo S; Zhou S; Shen R; Yang H; Chen H; Xie X
Oncotarget; 2017 Jan; 8(1):1141-1155. PubMed ID: 27901478
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
[TBL] [Abstract][Full Text] [Related]
17. [Management of extensive disease small cell lung cancer. Guidelines of clinical practice made by the European Lung Cancer Working Party].
Grigoriu B; Meert AP;
Rev Med Brux; 2014; 35(3):164-8. PubMed ID: 25102583
[TBL] [Abstract][Full Text] [Related]
18. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
19. Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions.
Allen J; Jahanzeb M
Clin Lung Cancer; 2008 Sep; 9(5):262-70. PubMed ID: 18953759
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer.
Han JY; Kim HT; Lim KY; Yoon SJ; Lee DH; Lee JS
J Thorac Oncol; 2008 Sep; 3(9):1039-45. PubMed ID: 18758308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
